Aquilo Capital Management, LLC Morpho Sys Ag Transaction History

Aquilo Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$30.28 - $35.72 $2.9 Million - $3.43 Million	-95,898 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$18.86 - $37.36 $1.69 Million - $3.36 Million	89,818 Added 1477.27%	95,898 $2.36 Million
Q4 2019 Feb 14, 2020	BUY	$26.07 - $36.32 $158,505 - $220,825	6,080 New	6,080 $217,000
Q1 2019 May 15, 2019	SELL	$22.55 - $29.84 $265,796 - $351,724	-11,787 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$21.96 - $31.02 $59,292 - $83,754	2,700 Added 29.71%	11,787 $298,000
Q3 2018 Nov 14, 2018	SELL	$26.64 - $35.66 $24,322 - $32,557	-913 Reduced 9.13%	9,087 $243,000
Q2 2018 Aug 14, 2018	BUY	$25.15 - $30.6 $251,500 - $306,000	10,000 New	10,000 $303,000

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Aquilo Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Aquilo Capital Management, LLC with notifications on news.